CIK 0001590877 · Non-accelerated filer<br>Smaller reporting company
REGENXBIO Inc.
Sign in to watch- Ticker
- RGNX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 471851754
- Phone
- 240-552-8181
- Business address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Former names
- ReGenX Biosciences, LLC
- Open-market buys, last 90 days
- $949,381
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$949,381. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-06-03 | Tasse Daniel Director | Grant or award · Stock Option (Right to Buy) | +15,324 | 15,324 | ||
| 2022-06-03 | STUMP DAVID C Director | Grant or award | +3,010 | 3,010 | ||
| 2022-06-03 | STUMP DAVID C Director | Grant or award · Stock Option (Right to Buy) | +15,324 | 15,324 | ||
| 2022-06-03 | MIGAUSKY GEORGE V Director | Grant or award | +3,010 | 3,010 | ||
| 2022-06-03 | MIGAUSKY GEORGE V Director | Grant or award · Stock Option (Right to Buy) | +15,324 | 15,324 | ||
| 2022-06-03 | KARABELAS ARGERIS N Director | Grant or award | +3,010 | 3,010 | ||
| 2022-06-03 | KARABELAS ARGERIS N Director | Grant or award · Stock Option (Right to Buy) | +15,324 | 15,324 | ||
| 2022-06-03 | Glucksmann Alexandra Director | Grant or award | +3,010 | 3,010 | ||
| 2022-06-03 | Glucksmann Alexandra Director | Grant or award · Stock Option (Right to Buy) | +15,324 | 15,324 | ||
| 2022-06-03 | Fox Allan M. Director | Grant or award | +3,010 | 3,010 | ||
| 2022-06-03 | Fox Allan M. Director | Grant or award · Stock Option (Right to Buy) | +15,324 | 15,324 | ||
| 2022-06-03 | Bennett Jean Director | Grant or award | +3,010 | 3,010 | ||
| 2022-06-03 | Bennett Jean Director | Grant or award · Stock Option (Right to Buy) | +15,324 | 15,324 | ||
| 2022-01-20 | Vasista Vittal Chief Financial Officer | Option exercise | +29,900 | $0.85 | $25K | 162,440 |
| 2022-01-20 | Vasista Vittal Chief Financial Officer | Option exercise · Employee Stock Option (Right to Buy) | −29,900 | 35,000 | ||
| 2022-01-03 | Vasista Vittal Chief Financial Officer | Grant or award | +8,900 | 132,540 | ||
| 2022-01-03 | Vasista Vittal Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +42,500 | 42,500 | ||
| 2022-01-03 | Simpson Curran Chief Oper. & Tech. Officer | Grant or award | +10,700 | 27,116 | ||
| 2022-01-03 | Simpson Curran Chief Oper. & Tech. Officer | Grant or award · Stock Option (Right to Buy) | +51,100 | 51,100 | ||
| 2022-01-03 | PAKOLA STEVE Chief Medical Officer | Sale | −1,598 | $33.75 | $54K | 8,250 |
Page 14 of 25 · 494 trades